Posted on 06/11/2008 in Pharmaceutical Company Product News ProStrakan has announced NewBridge Pharmaceuticals as partner for Sancuso in the Middle East and Africa.
Signing an exclusive licence and agreement with the United Arab Emirates-based company, ProStrakan is set to receive undisclosed upfront and milestone payments, subject to the reaching of approvals and targets.
The agreement applies to 59 countries across the Middle East and Africa and follows Sancuso's launch in the USA this week following approval from the country's Food and Drug Administration.
Sancuso is a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting.
The product has been shown to be as efficient as oral granisetron, while eradicating the need for repeated daily injections, resulting in a reduction of potential infection risk.
Dr Wilson Totten, ProStrakan's chief executive, said: "While ProStrakan's core markets are Europe and the US, we continue to seek out opportunities to create a revenue stream from our products in territories that are non-core, yet likely to be lucrative, for us."
Interim chief executive officer at NewBridge Pharmaceuticals, Dr Garrett Vygantas, added that the company intends to advance further to provide pharmaceutical care to the oncology market in the Middle East and Africa.
Based in Galashiels in Scotland, ProStrakan's development facilities are based at the same location and in Bedminster, USA.Other news stories from 06/11/2008
Read more in the Zenopa News Archive
How this news is generated
|
